Clinical-stage biopharmaceutical company
Opna Bio has raised €37M across 1 funding round from 3 investors, most recently a Series A round in Nov 2022. Based in Epalinges, Switzerland; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-22 | Series A | €37M |
| Longitude Capital,Menlo Ventures,Northpond Ventures |
| View deal → |
